Kinase News and Research

RSS

Study offers new hope to patients with rare brain cancer

sGBM is a rare type of brain cancer in adults. The incidence varies from 2 to 5 per million people per year. For example, if Hong Kong's base population of 7.5 million people is taken as a reference, over 15 people will be diagnosed with sGBM tumors annually.

2 Nov 2018

Researchers discover new antibiotic compounds

Researchers have identified new compounds that can target bacterial infection, potentially providing an answer to antibiotic resistance.

1 Nov 2018

CNIO researchers link MASTL protein to origin of thrombocytopenia

The Cell Division and Cancer Group of the Spanish National Cancer Research Centre has discovered that MASTL, the protein whose function in the organism has not yet been sufficiently investigated, plays an important role in controlling the cytoskeleton, the structure that gives shape to the cells, and enables their mobility and capacity for grouping.

1 Nov 2018

UA scientists aim to identify drug targets for rare pediatric cancer

Rhabdomyosarcoma is a rare cancer of the skeletal muscle that primarily affects pediatric patients. After diagnosis, about 3 out of 4 patients are cured with standard treatment. Survival rates drop to 17 percent if the disease comes back (recurs) and to 30 percent if it spreads (metastasizes).

1 Nov 2018

Study offers hope of early detection, treatment of liver cancer

Liver cancer is the second leading cause of cancer-related mortality worldwide, claiming 700,000 lives each year. Most cases are discovered too late for a cure -- but now a study offers hope of early detection, and targets for new treatments.

31 Oct 2018

Newly developed technology can predict large volumes of unknown biochemical reactions

Fujitsu Laboratories Ltd., the Insight Centre for Data Analytics, a data analytics research institution based in Ireland, and Fujitsu (Ireland) Limited today announced the development of a technology that makes it possible to predict large volumes of unknown chemical reactions, about twice as many as the conventional procedure.

31 Oct 2018

Scientists find ways to block nitration of amino acids to improve cancer immunotherapy

Immunotherapy -- harnessing T-cells to attack cancer cells in the body -- has given hope to patients who endure round after round of treatment, including chemotherapy, to little effect. For all of its promise, however, immunotherapy still benefits only a minority of patients -- a reality driving research in the field for ways to improve the relatively new approach.

30 Oct 2018

New findings highlight importance of inflammatory component in atherosclerosis pathogenesis

One of the main characteristics of atherosclerosis is the accumulation of lipids in the intimal layer of the arterial wall.

29 Oct 2018

Novel drug extends survival for women with HR-positive metastatic breast cancer

The drug palbociclib, used in combination with standard treatment, improved survival for women with hormone receptor-positive metastatic breast cancer, according to a large phase III clinical trial.

24 Oct 2018

Scientists develop new class of compounds for treatment of progressive neurodegenerative disorder

St. Jude Children's Research Hospital investigators have developed a new class of compounds that extended the lives and eased symptoms of mice with a progressive neurodegenerative human disorder.

23 Oct 2018

Study: Atg2 tethers pre-autophagosomal membrane to endoplasmic reticulum during autophagosome formation

Postdoctoral Researcher Tetsuya Kotani, Associate Professor Hitoshi Nakatogawa, Honorary Professor Yoshinori Ohsumi and colleagues at Tokyo Institute of Technology have analyzed the Atg protein Atg2, whose function had been completely unknown, and have discovered that Atg2 tethers the pre-autophagosomal membrane to the endoplasmic reticulum during autophagosome formation.

23 Oct 2018

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Treatment with the cyclin dependent kinase 4/6 inhibitor palbociclib achieves a clinically meaningful improvement in overall survival in patients with hormone receptor positive human epidermal growth factor receptor-2 negative advanced breast cancer that has relapsed or progressed on hormonal therapy, according to the final analysis of overall survival results from the PALOMA-3 study reported at ESMO 2018.

23 Oct 2018

Drugs approved for breast cancer treatment are effective and well tolerated in men

There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies to be reported at ESMO 2018.

23 Oct 2018

Study: Targeting specific genomic mutation in breast cancer improves survival

Targeting a common mutation in patients with hormone receptor positive (HR+) HER2 negative (HER2-) advanced breast cancer with the alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib significantly improves progression-free survival, according to late-breaking results reported at ESMO 2018.

22 Oct 2018

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

EUSA Pharma welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology clinical practice guidelines for advanced renal cell carcinoma, anticipated to be published at the end of this year.

22 Oct 2018

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase inhibitor, axitinib, significantly improves progression-free survival in previously untreated patients with advanced renal cell carcinoma in a phase 3 study, according to results presented at ESMO 2018 Congress.

22 Oct 2018

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.

22 Oct 2018

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated preliminary results from its ongoing Phase 1 clinical study of DCC-2618, the company's broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors as a proffered paper presentation at the European Society of Medical Oncology 2018 Congress in Munich, Germany.

22 Oct 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

Research provides insight into neurobiology of aggression and bullying

Duke-NUS researchers have discovered that a growth factor protein, called brain-derived neurotrophic factor, and its receptor, tropomyosin receptor kinase B affects social dominance in mice. The research has implications for understanding the neurobiology of aggression and bullying.

20 Oct 2018

Kinase News and Research

Study offers new hope to patients with rare brain cancer

Researchers discover new antibiotic compounds

CNIO researchers link MASTL protein to origin of thrombocytopenia

UA scientists aim to identify drug targets for rare pediatric cancer

Study offers hope of early detection, treatment of liver cancer

Newly developed technology can predict large volumes of unknown biochemical reactions

Scientists find ways to block nitration of amino acids to improve cancer immunotherapy

New findings highlight importance of inflammatory component in atherosclerosis pathogenesis

Novel drug extends survival for women with HR-positive metastatic breast cancer

Scientists develop new class of compounds for treatment of progressive neurodegenerative disorder

Study: Atg2 tethers pre-autophagosomal membrane to endoplasmic reticulum during autophagosome formation

Study reveals new treatment option for women with advanced breast cancer resistant to hormone therapy

Drugs approved for breast cancer treatment are effective and well tolerated in men

Study: Targeting specific genomic mutation in breast cancer improves survival

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Deciphera presents Phase 1 clinical results of DCC-2618 in patients with gastrointestinal stromal tumors

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Research provides insight into neurobiology of aggression and bullying

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News